Korean journal of clinical oncology最新文献

Metastasis-associated protein 1: a druggable target in cancer treatment. 转移相关蛋白1：癌症治疗的可药物靶点

Korean journal of clinical oncology Pub Date : 2025-04-01 Epub Date: 2025-04-30 DOI: 10.14216/kjco.24323

Madhusudana Pulaganti, Kireeti Anthati Soma, Rekha Mandla, Bhavana Cherukuthota, Haseena Dudekula

{"title":"Metastasis-associated protein 1: a druggable target in cancer treatment.","authors":"Madhusudana Pulaganti, Kireeti Anthati Soma, Rekha Mandla, Bhavana Cherukuthota, Haseena Dudekula","doi":"10.14216/kjco.24323","DOIUrl":"https://doi.org/10.14216/kjco.24323","url":null,"abstract":"Cancer treatment has undergone significant transformation with the emergence of molecularly targeted drugs, aiming to exploit specific vulnerabilities within cancer cells while sparing normal tissues. One critical aspect of this approach is the identification of druggable targets, proteins or pathways that can be modulated by pharmacological agents to inhibit tumor growth or metastasis. The metastasis-associated protein 1 (MTA1) has emerged as a promising druggable target due to its multifaceted roles in cancer progression, including regulation of gene expression, chromatin remodeling, and promotion of epithelial-mesenchymal transition. This abstract provides an overview of the current landscape of MTA1 as a druggable target in cancer therapy, highlighting its diverse functions across different malignancies and its potential as a predictive biomarker for therapeutic response. Finally, it explores future directions and novel strategies for exploiting MTA1 inhibition in precision oncology. Overall, understanding the druggable potential of MTA1 offers new avenues for the development of innovative cancer treatments with improved efficacy and reduced toxicity, ultimately leading to better clinical outcomes for cancer patients.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"21 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor budding in invasive breast carcinoma and its association with clinicopathological parameters: an experience from a tertiary care center in India. 浸润性乳腺癌的肿瘤萌芽及其与临床病理参数的关系：来自印度三级保健中心的经验。

Korean journal of clinical oncology Pub Date : 2025-04-01 Epub Date: 2025-04-30 DOI: 10.14216/kjco.24317

Asmita Shah, Shaivy Malik, Adil Aziz Khan, Charanjeet Ahluwalia

{"title":"Tumor budding in invasive breast carcinoma and its association with clinicopathological parameters: an experience from a tertiary care center in India.","authors":"Asmita Shah, Shaivy Malik, Adil Aziz Khan, Charanjeet Ahluwalia","doi":"10.14216/kjco.24317","DOIUrl":"https://doi.org/10.14216/kjco.24317","url":null,"abstract":"Purpose: Breast cancer is one of the most common cancers globally, with an increasing incidence rate. It is a heterogeneous disease, and early metastasis remains a challenge. Tumor budding, defined as single tumor cells or small clusters at the invasive front, has been suggested as a prognostic marker in various cancers, including breast cancer. This study aims to evaluate tumor budding in invasive breast carcinoma using the International Tumor Budding Consensus Conference (ITBCC) scoring system and explore its association with pathological characteristics and prognosis.Methods: A retrospective study was conducted on 100 mastectomy specimens of histopathologically confirmed invasive breast carcinoma, excluding cases that underwent chemotherapy or radiotherapy. Tumor budding was classified as low, intermediate, or high based on the ITBCC scoring method, and associations with clinicopathological features were analyzed using appropriate statistical tests.Results: Tumor budding was classified as high in 52% of cases. A significant association was found between high tumor budding and higher tumor grade (P<0.001), negative estrogen receptor and progesterone receptor status (P<0.001), positive HER2neu status (P=0.003), and high Ki-67 levels (P<0.001). High tumor budding was also linked to higher T stage, and dermal lymphovascular invasion (P=0.001). Our findings support previous studies showing that high tumor budding is associated with poor prognostic factors such as higher tumor grade, negative hormone receptor status, and higher T stage.Conclusion: Tumor budding is a potential prognostic marker in breast cancer, associated with more aggressive tumor characteristics.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"21 1","pages":"13-19"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alterations in portal vein confluence during gastric cancer surgery: two case reports. 胃癌手术中门静脉汇合的改变：2例报告。

Korean journal of clinical oncology Pub Date : 2025-04-01 Epub Date: 2025-04-30 DOI: 10.14216/kjco.24329

Sa-Hong Kim, Franco José Signorini, Kyoyoung Park, Chungyoon Kim, Jeesun Kim, Yo-Seok Cho, Seong-Ho Kong, Do-Joong Park, Hyuk-Joon Lee, Han-Kwang Yang

{"title":"Alterations in portal vein confluence during gastric cancer surgery: two case reports.","authors":"Sa-Hong Kim, Franco José Signorini, Kyoyoung Park, Chungyoon Kim, Jeesun Kim, Yo-Seok Cho, Seong-Ho Kong, Do-Joong Park, Hyuk-Joon Lee, Han-Kwang Yang","doi":"10.14216/kjco.24329","DOIUrl":"https://doi.org/10.14216/kjco.24329","url":null,"abstract":"This article presents two cases of extrahepatic portal vein anomalies that can be challenging during lymph node (LN) dissection in gastric cancer surgery. The first case was a participant for a clinical trial assessing the completeness of D2 LN dissection. The trial utilized near-infrared (NIR) lymphangiography with indocyanine green only after completing dissection of a certain topological LN station to detect any residual lymphatic tissue. However, the patient was excluded from the trial due to an unexpected extrahepatic portal vein confluence anomaly and aberrant common hepatic artery. Consequently, continuous lymphatic navigation with NIR imaging was utilized for remaining surgery. The second case featured a patient with an anteriorly positioned splenic vein, hindering LN dissection along the left gastric artery. Preoperative identification of great vessel anomalies around the stomach is critical to prevent life-threatening complications during LN dissection in gastric cancer surgery. Augmented imaging technology can be a valuable tool in ensuring oncologic safety and precision.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"21 1","pages":"40-46"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing cancer vaccine with carcinoembryonic antigen and IGF-1R as immunostimulants using immunoinformatics approach. 利用免疫信息学方法开发以癌胚抗原和IGF-1R为免疫刺激剂的癌症疫苗。

Korean journal of clinical oncology Pub Date : 2025-04-01 Epub Date: 2025-04-30 DOI: 10.14216/kjco.24326

Louis Odinakaose Ezediuno, Michael Asebake Ockiya, Luqman Oluwaseun Awoniyi, Adeola Oyepeju Sangodare, Kehinde Busuyi David, Faith Owabhel Robert

{"title":"Developing cancer vaccine with carcinoembryonic antigen and IGF-1R as immunostimulants using immunoinformatics approach.","authors":"Louis Odinakaose Ezediuno, Michael Asebake Ockiya, Luqman Oluwaseun Awoniyi, Adeola Oyepeju Sangodare, Kehinde Busuyi David, Faith Owabhel Robert","doi":"10.14216/kjco.24326","DOIUrl":"https://doi.org/10.14216/kjco.24326","url":null,"abstract":"Purpose: Colorectal cancer (CRC) remains a significant global health burden, necessitating innovative approaches for prevention and treatment. This study proposes a multiepitope vaccine targeting carcinoembryonic antigen (CEA) and insulin-like growth factor-1 receptor (IGF-1R), two prominent biomarkers associated with CRC progression.Methods: Sequences of CEA and IGF-1R proteins were retrieved from NCBI databank, the sequences were aligned on the MEGA5 tool to identify conserved regions. Immunological and structural predictive analysis which include antigenic potential prediction, cytotoxic T-lymphocytes (CTLs), helper-T lymphocytes (HTLs), B-cell epitopes predictions, and prediction of the vaccine secondary and tertiary structure were performed. The vaccine was evaluated to validate its physiochemical and immunological properties. To determine the binding energy and domain, the tertiary structure of the vaccine was docked to Toll-like receptor 4, and viewed on PyMOL and LigPlot+ tools.Results: CEA and IGF-1R were revealed to be highly antigenic, and non-allergens demonstrating the capacity to elicit robust immune responses, which include CTLs, HTLs, and B cells activation. The secondary structure revealed a conformation closely resembling native protein, with alpha helices, beta sheets, and coils, indicative of favorable interactions. Tertiary structure prediction predicted five models, model 0 was selected and validated due its highest confidence, and validation revealed that 87.5% of residues were within favored regions, with a z-score of 4.03. Molecular docking predicted strong binding complex with low binding energy.Conclusion: Based on our analysis, the proposed multiepitope vaccine holds promise as an effective preventive measure against colorectal cancer development.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"21 1","pages":"20-31"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resident shortages and their impact on surgical care, defensive medicine, and patient management: a retrospective study in South Korea. 住院医师短缺及其对外科护理、防御性医疗和患者管理的影响：韩国的一项回顾性研究。

Korean journal of clinical oncology Pub Date : 2025-04-01 Epub Date: 2025-04-30 DOI: 10.14216/kjco.25331

Jeong Hee Han, Byoung Chul Lee, Jung Bum Choi, Hong Jae Jo, Jae Kyun Park, Hyae Jin Kim, Eun Ji Park, Young Hoon Jung, Chang In Choi

{"title":"Resident shortages and their impact on surgical care, defensive medicine, and patient management: a retrospective study in South Korea.","authors":"Jeong Hee Han, Byoung Chul Lee, Jung Bum Choi, Hong Jae Jo, Jae Kyun Park, Hyae Jin Kim, Eun Ji Park, Young Hoon Jung, Chang In Choi","doi":"10.14216/kjco.25331","DOIUrl":"https://doi.org/10.14216/kjco.25331","url":null,"abstract":"Purpose: This study aimed to evaluate the impact of declining surgical residency program enrollment on patient care and outcomes in colorectal cancer surgeries.Methods: This retrospective observational study included 676 patients (410 males; median age: 69 years) who underwent colorectal cancer surgery at Pusan National University Hospital between January 2018 and June 2024. Patients were divided into Group A (before December 31, 2023; with residents) and Group B (after January 1, 2024; without residents). All surgeries were performed by a single attending surgeon.Results: Preoperative variables were comparable between groups. Group A had more emergency and open surgeries, and a higher proportion of advanced-stage cancers. Overall complication rates were similar, but Group B had a longer hospital stay (9.72 days vs. 11.95 days). Specific complications such as anastomotic leakage and surgical site infections differed significantly. The overall number of surgical procedures declined markedly in 2024 compared to 2018 (77.1% vs. 49.9%).Conclusion: The absence of residents did not increase overall complication rates but was associated with longer hospital stays and shifts in clinical practice. Greater reliance on attending surgeons contributed to more defensive decision-making and conservative patient management. Addressing these issues requires systemic reforms, including multidisciplinary collaboration and legal protections to improve surgical care.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"21 1","pages":"32-39"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic significance of tumor budding in endometrial cancer: clinicopathological insights. 子宫内膜癌肿瘤出芽的预后意义：临床病理观察。

Korean journal of clinical oncology Pub Date : 2025-03-05 DOI: 10.14216/kjco.24306

Ashi Dubey, Sana Ahuja, Sufian Zaheer

{"title":"Prognostic significance of tumor budding in endometrial cancer: clinicopathological insights.","authors":"Ashi Dubey, Sana Ahuja, Sufian Zaheer","doi":"10.14216/kjco.24306","DOIUrl":"https://doi.org/10.14216/kjco.24306","url":null,"abstract":"Purpose: Endometrial cancer is one of the most common gynecological cancers worldwide, with rising incidence rates. Despite therapeutic advances, it remains a significant cause of cancer-related deaths. Tumor budding (TB), characterized by single cells or small clusters at the invasive tumor front, is a recognized prognostic marker in several cancers but is less studied in endometrial cancer.Methods: This prospective cohort study included 30 patients with endometrial cancer who underwent surgical resection from January 2022 to June 2023. Formalin-fixed, paraffin-embedded tissue blocks were reviewed by two blinded pathologists. TB at the invasive front was assessed using hematoxylin and eosin staining. Clinical and pathological parameters, including age, histological type, grade, stage, myometrial invasion, lymphovascular space invasion, and nodal involvement, were recorded. Fisher's exact and chi-square tests were used for statistical analyses.Results: Most patients (60%) were aged 51-60 years, with 93.3% diagnosed with endometrioid adenocarcinoma. Tumors were graded as 40% grade 1, 43.3% grade 2, and 16.7% grade 3. Staging showed 36.7% FIGO IA, 36.7% IB, 16.7% II, and 10% III. TB was classified as low (70%), intermediate (23.3%), and high (6.7%). Higher TB levels were significantly associated with higher tumor grade (P=0.03), advanced stage (P=0.02), and nodal involvement (P=0.01).Conclusion: TB correlates with adverse features in endometrial cancer, including higher grade, advanced stage, and nodal involvement. These findings underscore TB's potential as a prognostic marker, warranting validation in larger studies and exploration of its molecular basis to guide personalized treatments.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143559744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives. 癌症免疫治疗的发展：对其历史和当前前景的全面回顾。

Korean journal of clinical oncology Pub Date : 2024-12-01 Epub Date: 2024-12-31 DOI: 10.14216/kjco.24009

Sana Ahuja, Sufian Zaheer

{"title":"The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.","authors":"Sana Ahuja, Sufian Zaheer","doi":"10.14216/kjco.24009","DOIUrl":"10.14216/kjco.24009","url":null,"abstract":"Cancer immunotherapy uses the body's immune system to combat cancer, marking a significant advancement in treatment. This review traces its evolution from the late 19th century to its current status. It began with William Coley's pioneering work using bacterial toxins to stimulate the immune system against cancer cells, establishing the foundational concept of immunotherapy. In the mid-20th century, cytokine therapies like interferons and interleukins emerged, demonstrating that altering the immune response could reduce tumors and highlighting the complex interplay between cancer and the immune system. The discovery of immune checkpoints, regulatory pathways that prevent autoimmunity but are exploited by cancer cells to evade detection, was a pivotal development. Another major breakthrough is CAR-T cell therapy, which involves modifying a patient's T cells to target cancer-specific antigens. This personalized treatment has shown remarkable success in certain blood cancers. Additionally, cancer vaccines aim to trigger immune responses against tumor-specific or associated antigens, and while challenging, ongoing research is improving their efficacy. The historical progression of cancer immunotherapy, from Coley's toxins to modern innovations like checkpoint inhibitors and CAR-T cell therapy, underscores its transformative impact on cancer treatment. As research delves deeper into the immune system's complexities, immunotherapy is poised to become even more crucial in oncology, offering renewed hope to patients globally.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"20 2","pages":"51-73"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 and cancer: reflections 2 years into the pandemic. 2019冠状病毒病与癌症：大流行两年后的思考

Korean journal of clinical oncology Pub Date : 2024-12-01 Epub Date: 2024-12-31 DOI: 10.14216/kjco.24008

Kamal Saba, Manisha Dhawaria, Aamir Javed

引用次数: 0

The unseen spread-Schnitzler's metastasis unveiled: a case report. 看不见的扩散-施尼茨勒转移揭幕：一份病例报告。

Korean journal of clinical oncology Pub Date : 2024-12-01 Epub Date: 2024-12-31 DOI: 10.14216/kjco.24013

Jeya Anand Ayyamperumal, Maravadi Jayaraman Chandrabose Ambedkar, Anand Lakshmanan, Jeswanth Satyanesan

引用次数: 0

Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report. 使用细胞因子诱导的杀伤细胞疗法和大剂量维生素C长期抑制胆管癌肿瘤：1例报告。

Korean journal of clinical oncology Pub Date : 2024-12-01 Epub Date: 2024-12-31 DOI: 10.14216/kjco.24012

Kangseok Kim, Hyunhye Wang, Jiewon Lee, Changhwan Yeom

{"title":"Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report.","authors":"Kangseok Kim, Hyunhye Wang, Jiewon Lee, Changhwan Yeom","doi":"10.14216/kjco.24012","DOIUrl":"10.14216/kjco.24012","url":null,"abstract":"This case study explores the effectiveness of autologous cytokine-induced killer (CIK) cell-based immunotherapy in a 49-year-old male patient with inoperable stage IIIb cholangiocarcinoma, characterized by high levels of the sodium-dependent vitamin C transporter-2 (SVCT2) in immune cells. Despite an initial lack of tumor reduction following chemotherapy, the patient showed a significant decrease in tumor markers and stabilization of the tumor after undergoing radiation and proton therapy. Subsequently, CIK cell therapy, combined with high-dose vitamin C, was administered 52 times over 6 years. The patient's tumor size reduced, and no cancer activity was detected for 7 years and 10 months post-diagnosis, indicating a successful long-term outcome without recurrence. This study suggests that CIK cell therapy, particularly in patients with elevated SVCT2 levels, may offer a promising adjuvant treatment for cholangiocarcinoma and potentially other cancers. Further research is needed to validate SVCT2 as a biomarker for the effectiveness of CIK cell therapy.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"20 2","pages":"84-87"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0